Business Summary
The company has a portfolio of 5 programs in the development phase, including LEUKOTAC® (Inolimomab), an immunotherapy antibody demonstrating a clinical benefit in Phase 3 of a rare disease with a very poor prognosis: acute steroid resistant reaction of the graft against the host.
Managers
Managers | Title | Age | Since |
---|---|---|---|
Martine Brandt
FOU | Founder | - | 31/12/12 |
Thierry Menguy
FOU | Founder | - | 31/12/12 |
Vanessa Duong
FOU | Founder | - | 31/12/12 |
Founder | - | 31/12/12 | |
Mizrahi Jacques
CTO | Chief Tech/Sci/R&D Officer | 70 | 31/12/13 |
Eric Quéméneur
CTO | Chief Tech/Sci/R&D Officer | 60 | - |
David Liens
CTO | Chief Tech/Sci/R&D Officer | 59 | 31/12/16 |
Corporate Officer/Principal | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | - | 31/12/12 | |
Eric Quéméneur
CTO | Chief Tech/Sci/R&D Officer | 60 | - |
Mizrahi Jacques
CTO | Chief Tech/Sci/R&D Officer | 70 | 31/12/13 |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
+31.37% | 588B | |
-2.60% | 364B | |
+20.83% | 326B | |
+5.69% | 285B | |
+14.83% | 239B | |
+9.93% | 210B | |
-6.95% | 200B | |
+10.77% | 167B | |
+0.10% | 161B |